Evidence in Populations Under‑Represented in Clinical Trials
Evidence is sought to understand the use, outcomes, and lived experiences of individuals receiving CAB + RPV LA, particularly among populations not represented or underrepresented in pivotal clinical trials.
Populations of Interest is open and may include, but not limited to: women across the age and reproductive continuum, individuals who have fallen out of care (where CAB + RPV LA may facilitate re-engagement in care opportunities), adherence‑challenged individuals, long‑term survivors (i.e., individuals having a HIV diagnosis prior to 1996), older adults (EU region only), treatment naive individuals switching soon after attaining initial viral suppression with oral ART.
ViiV ISR Area Of Interest Overview Drug/Product Alignment ViiV Products in Scope: Cabotegravir
Treatment Type: Long Acting-Treatment
Specify the Treatment Type:
Area of Interest/DataGap Description Core Focus Area: Efficacy/Effectiveness, Quality of LIfe
Example Research Question(s):
Desirable Study Parameters Populations of Interest: All Patient Types
Geographical Regions: Global
Version 20250909-disp